Search the Newsreel

Relay Therapeutics, Inc. $RLAY Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 47.9% in the first quarter, now owning 174,099 shares valued at $1.73 million. Despite institutional ownership of nearly 97%, the company missed analyst expectations on its last quarterly earnings and revenue. …

Reliance Communications Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Religare Enterprises Q1 Results: Consolidated loss widens to ₹7,673 lakh

JBT Marel Corporation $JBTM Stake Cut by Cetera Investment Advisers

Cetera Investment Advisers significantly reduced its stake in JBT Marel Corporation ($JBTM) by 91.9% in the first quarter, selling over 110,000 shares. Despite this, other institutional investors increased their positions, with institutional ownership remaining high at 98.92%. JBT Marel reported mixed financial results, missing …

Reliance Chemotex Q1 Results: Net Profit Rises 36% YoY to ₹1.37 crore

Prelude Narrows Loss In Q2 On Lower Costs; Expects Initiation Of PRT13722 Phase 1 In Q4 FY26

(RTTNews) - Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision-oncology company, reported second quarter results, showing a narrower loss primarily driven by increased revenue and reduced Research and Development (R&D) costs. Company Profile Prelude is developing therapies for cancers with a high unmet need. Its …

Reliance Worldwide Corporation Ltd (ASX:RWC) Gains: Is Housing Demand Providing Tailwinds?

Cracker Barrel (CBRL) CEO David Deno granted RSUs and 7,434 stock options

Cracker Barrel Old Country Store, Inc. (CBRL) CEO David J. Deno was granted 3,565 time-based restricted stock units (RSUs) and 7,434 stock options on August 10, 2026. Both awards are employment-related and will vest on August 10, 2029, contingent on his continued employment. The …

Relmada Therapeutics Inc (RLMD) Stock Price, Trades & News

This page provides a detailed overview of Relmada Therapeutics Inc (RLMD) stock, including its current price, market capitalization, financial strength, growth, momentum, and profitability ranks. It also lists upcoming earnings dates, past stock events, and recent news articles related to the company's financial results …

Should Upbeat Earnings Revisions and Top Zacks Rank Require Action From Reliance (RS) Investors?

JQUA's Quality Strategy Continues To Beat Broader Indices And Peers, Capturing Broadening Stock Market Trends

Religare Enterprises consolidated net loss narrows to ₹47 crore in Q1FY27

How Relx Plc Plc American Depositary Shares (each Representing One) (RELX) Affects Rotational Strategy Timing

The article analyzes how Relx Plc American Depositary Shares (RELX) impact rotational strategy timing, highlighting weak near-term sentiment potentially challenging mid-term strength within a broader long-term weak bias. It presents institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe …

Religare Enterprises Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Operational Traction Restores Investors’ Confidence in Cracker Barrel Old Country Store (CBRL)

Signia Capital Management, a boutique money management firm focusing on Small-Micro Cap and Small Cap Value investing, released its second-quarter 2026 investor letter for "Signia Small Cap Value Strategy". A copy of the letter can be downloaded here. The Small Cap Value approach targets …

These Analysts Think Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Sales Are Under Threat

Analysts have downgraded their revenue forecasts for Relay Therapeutics (RLAY) for 2026, cutting estimates from US$12m to US$11m and expecting increased losses per share to US$1.60. Despite the lowered outlook, the consensus price target remains unchanged at US$26.77, suggesting that the weaker earnings are …

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Consensus Recommendation of "Hold" from Analysts

Prelude Therapeutics (NASDAQ:PRLD) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $7.67. The company recently reported better-than-expected quarterly earnings and revenue, with an EPS of -$0.14 against an estimate of -$0.20, and revenue of $5.70 million exceeding …

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics reported its Q2 2026 financial results, highlighting steady execution across its pipeline. The company plans to initiate a Phase 1 study for PRT13722, a KAT6A degrader for HR+ breast cancer, in Q4 2026, and enrollment continues for its JAK2V617F inhibitor, PRT12396. Prelude …

Madden NYC partners with Reliance Brands to enter India

Madden NYC, the footwear label owned by US company Steve Madden, has entered the Indian market with a women's footwear range sold online and through selected stores. The collection is available through Steve Madden's website, as well as retail outlets in Bengaluru, Hyderabad, Mumbai, …

Religare Enterprises grants 13,195 ESOPs at ₹227.35 per share

MTI Wireless Edge to Present Interim 2026 Results and Engage Investors Online

Aurelia Metals (ASX:AMI) Converts Production Gains Into Record Cash Flow

Ambarella Q2 Results: Earnings Call Scheduled for September 3, 2026

Ambarella, Inc. has announced its second-quarter fiscal year 2027 earnings conference call for September 3, 2026, at 1:30 p.m. Pacific Time, with the earnings release occurring after market close on the same day. Participants wishing to ask questions must complete a two-step online registration …

Ambarella to Hold Second Quarter Fiscal 2027 Earnings Conference Call on September 3, 2026

Ambarella SANTA CLARA, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced it will hold its second quarter fiscal year 2027 earnings conference call on Thursday, September 3, 2026 at 1:30 p.m. (Pacific Time). The …

Ambarella to Release Fiscal Q2 Results After Sept. 3 Close

Ambarella Announces Second Quarter Fiscal Year 2027 Earnings Conference Call to be Held September 3, 2026

Ambarella SANTA CLARA, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced it will hold its second quarter fiscal year 2027 earnings conference call on Thursday, September 3, 2026 at 1:30 p.m. (Pacific Time). The …

Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear

Prelude Therapeutics (PRLD) stock rallied by 10.1% after its Q2 2026 earnings report showed a significant narrowing of losses, with revenue increasing from zero to US$5.70 million. While the company's financials appear cleaner due to collaborations, the article highlights that key 2026 clinical milestones, …

RELX plc (REL) Q2 2024 Earnings Report - Results, Call & Slides

RELX plc (GB:REL) reported its Q2 2024 earnings, with an actual EPS of £0.59, matching the consensus. However, actual revenue was £4.64 billion, missing the expected £4.74 billion by £103.33 million, despite a 3.16% year-over-year revenue growth. The company's next earnings report is estimated …

RELX plc (REL) Q4 2023 Earnings Report - Results, Call & Slides

Estrella adds fourth site to EB103 lymphoma trial

Estrella Immunopharma Inc. has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103, an investigational T-cell therapy for B-cell non-Hodgkin's lymphoma. This expansion aims to evaluate the therapy's safety and efficacy, with data expected to …

Reliance Global Consolidates Entire Digital Treasury Into Zcash Privacy Coin

Reliance Global Group (NASDAQ: RELI) has strategically shifted its entire digital asset treasury into Zcash, moving from a diversified crypto portfolio to a single-asset approach focused on privacy. This decision was based on a comprehensive review by its crypto advisory team, which concluded that …

Lorenzini Apparels Q1 Results: Net profit surges 125% YoY to ₹2.17 crore

Relx unit LexisNexis wins $163 million Login.gov identity resolution order from GSA

Relx unit LexisNexis Risk Solutions secured a $163 million order from the U.S. GSA on May 1, 2026, to enhance Login.gov's next-generation identity verification. The award covers three functional areas, including identity resolution, document authentication, biometric verification, behavioral intelligence, and fraud detection. While the …

Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Prelude Therapeutics (NASDAQ:PRLD) announced its quarterly earnings, reporting an adjusted loss of $0.14 per share, surpassing analyst estimates by $0.03. The company also exceeded revenue expectations, achieving $5.70 million against a consensus of $4.78 million. Despite mixed analyst sentiment with a "Hold" consensus and …

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma has announced the activation of University Hospitals Cleveland Medical Center as the fourth clinical site for its STARLIGHT-1 Phase I/II clinical trial. This trial is evaluating EB103, an ARTEMIS® T-cell therapy targeting CD19, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. …

Estrella adds fourth site to EB103 lymphoma trial By Investing.com

Estrella Immunopharma Inc. (NASDAQ:ESLA) has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103. This trial evaluates EB103, a CD19-redirected T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The company anticipates using …